1. ALLA AKTIER
  2. NYHETER
  3. ANNEXIN PHARMACEUTICALS

Annexin Pharmaceuticals

Nyheter Annexin Pharmaceuticals Nyheter alla bolag

Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion

Annexin Pharmaceuticals AB today announces that Redeye has published an interview with the company's CEO Anders Haegerstrand and CSO/CMO Anna Frostegård regarding the ongoing clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye diseases diabetic retinopathy (DR) and retinal vein occlusion (RVO) and a summary of the year. A webinar about RVO and the Annexin study conducted by Professor Paulo-Eduardo Stanga is also available.

Annexin has recently announced that the first two patients have been dosed in the ongoing Phase 2a study, which is being conducted at The Retina Clinic in London under the leadership of Professor Paulo-Eduardo Stanga. In the interview, Anders Haegerstrand and Anna Frostegård give an insight into why the study is important, inform about the chosen study design and the type of data that can be expected to show within DR and RVO, as well as how the company's partnership discussions are progressing.
The interview can be seen here: Redeye interview

Recently, Professor Paulo-Eduardo Stanga at The Retina Clinic held a webinar, Retinal Vein Occlusion: Clinical Features, Current Management, & Future Developments, where he describes RVO and reviews ANXV as a potential treatment for RVO and the ongoing phase 2a study. Information about Annexin's study begins at 15:30 minutes into the video.
The webinar can be viewed here: Retinal Vein Occlusion: Clinical Features, Current Management, & Future Developments

For further information, please contact:
Anders Haegerstrand, CEO
Phone: +46 (0)70 575 50 37
Mail: anders.haegerstrand@annexinpharma.com

About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5.
The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company´s Certified Adviser.

Attachments
Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion

Datum 2025-12-18, kl 12:30
Källa MFN
Bifogade filer
Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!